Dr Debashis Sarker
Clinical Reader in Experimental Oncology
Research interests
- Cancer
Contact details
Biography
Debashis Sarker is Reader in Experimental Oncology within the Comprehensive Cancer Centre and Consultant Medical Oncologist at Guy's, St Thomas' and King's College Hospitals. His main research interests are in first-in-human development of novel molecularly targeted agents, molecular and cellular immunotherapies and is the co-lead of King’s Health Partners Experimental Cancer Medicine Centre. He specialises in management of liver, pancreatic and neuroendocrine cancers with a particular focus in developmental therapeutics and genomics. He is the clinical co-lead at NHSE South East Genomic Medicine Service and Laboratory Hub and is the Deputy Director of NIHR Guy’s and St Thomas Clinical Research Facility.
A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases
Plummer, R., Greystoke, A., Naylor, G., Sarker, D., Anam, A. K., Prenen, H., Teuwen, L. A., Van Cutsem, E., Dekervel, J., Haugk, B., Ness, T., Bhoi, S., Jensen, M., Morris, T., Baumann, P., Sjögren, N., Tunblad, K., Wallberg, H., Öberg, F. & Evans, T. R. J., 2024, In: Journal of Hepatocellular Carcinoma. 11, p. 2033-2047 15 p.Research output: Contribution to journal › Article › peer-review
Next-generation sequencing and molecular therapy
Morton, C., Sarker, D. & Ross, P., Jan 2023, In: Clinical Medicine, Journal of the Royal College of Physicians of London. 23, 1, p. 65-69 5 p.Research output: Contribution to journal › Article › peer-review
Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma
Ryoo, B.-Y., Palmer, D. H., Park, S. R., Rimassa, L., Sarker, D., Daniele, B., Steinberg, J., López, B. & Lim, H. Y., Mar 2022, In: CLINICAL DRUG INVESTIGATION. 42, 3, p. 283Research output: Contribution to journal › Article › peer-review
Next-generation sequencing and molecular therapy
Morton, C., Sarker, D. & Ross, P., Jan 2023, In: Clinical medicine (London, England). 23, 1, p. 65-69 5 p.Research output: Contribution to journal › Article › peer-review
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer
Jones, R., Plummer, R., Moreno, V., Carter, L., Roda, D., Garralda, E., Kristeleit, R., Sarker, D., Arkenau, T., Roxburgh, P., Walter, H. S., Blagden, S., Anthoney, A., Klencke, B. J., Kowalski, M. M. & Banerji, U., 15 Jan 2023, In: Clinical Cancer Research. 29, 2, p. 331-340 10 p.Research output: Contribution to journal › Article › peer-review
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
Kristeleit, R., Plummer, R., Jones, R., Carter, L., Blagden, S., Sarker, D., Arkenau, T., Evans, T. R. J., Danson, S., Symeonides, S. N., Veal, G. J., Klencke, B. J., Kowalski, M. M. & Banerji, U., 27 Jul 2023, In: British journal of cancer. 129, 1, p. 38-45 8 p.Research output: Contribution to journal › Article › peer-review
CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells
Samain, R., Maiques, O., Monger, J., Lam, H., Candido, J., George, S., Ferrari, N., Kohihammer, L., Lunetto, S., Varela, A., Orgaz, J. L., Vilardell, F., Olsina, J. J., Matias-Guiu, X., Sarker, D., Biddle, A., Balkwill, F. R., Eyles, J., Wilkinson, R. W. & Kocher, H. M. & 3 others, Calvo, F., Wells, C. M. & Sanz-Moreno, V., 2023, In: Science Advances. 9, 42, adi0244.Research output: Contribution to journal › Article › peer-review
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
Propper, D. J., Gao, F., Saunders, M. P., Sarker, D., Hartley, J. A., Spanswick, V. J., Lowe, H. L., Hackett, L. D., Ng, T. T., Barber, P. R., Weitsman, G. E., Pearce, S., White, L., Lopes, A., Forsyth, S. & Hochhauser, D., 19 Jan 2023, In: British journal of cancer. 128, 2, p. 245-254 10 p.Research output: Contribution to journal › Article › peer-review
Revitalising cancer trials post-pandemic: time for reform
Morton, C., Sullivan, R., Sarker, D., Posner, J. & Spicer, J., 12 Apr 2023, In: British journal of cancer. 128, 8, p. 1409-1414 6 p.Research output: Contribution to journal › Article › peer-review
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Verset, G., Borbath, I., Karwal, M., Verslype, C., Van Vlierberghe, H., Kardosh, A., Zagonel, V., Stal, P., Sarker, D., Palmer, D. H., Vogel, A., Edeline, J., Cattan, S., Kudo, M., Cheng, A. L., Ogasawara, S., Daniele, B., Chan, S. L., Knox, J. J. & Qin, S. & 6 others, Siegel, A. B., Chisamore, M., Hatogai, K., Wang, A., Finn, R. S. & Zhu, A. X., 15 Jun 2022, In: Clinical Cancer Research. 28, 12, p. 2547-2554 8 p.Research output: Contribution to journal › Review article › peer-review
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
KEYNOTE-224 investigators, May 2022, In: European Journal of Cancer. 167, p. 1-12 12 p.Research output: Contribution to journal › Article › peer-review
Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation-Results from the MACPIE-I study
Kundalia, K., Hakeem, A., Papoulas, M., Mcphail, M., Reddy, S., Peddu, P., Kibriya, N., Atkinson, S., Prachalias, A., Srinivasan, P., Heaton, N., Sarker, D., Ross, P., Zen, Y. & Menon, K., Oct 2021, In: European Journal of Surgical Oncology. 47, 10, p. 2571-2578 8 p.Research output: Contribution to journal › Article › peer-review
Upregulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer
Hashimoto, A., Sarker, D., Reebye, V., Jarvis, S., Sodergren, M. H., Kossenkov, A., Sanseviero, E., Raulf, N., Vasara, J., Andrikakou, P., Meyer, T., Huang, K. W., Plummer, R., Chee, C. E., Spalding, D., Pai, M., Khan, S., Pinato, D. J., Sharma, R. & Basu, B. & 11 others, Palmer, D., Ma, Y. T., Evans, J., Habib, R., Martirosyan, A., Elasri, N., Reynaud, A., Rossi, J. J., Cobbold, M., Habib, N. A. & Gabrilovich, D. I., 15 Nov 2021, In: Clinical Cancer Research. 27, 21, p. 5961-5978 18 p.Research output: Contribution to journal › Article › peer-review
A phase I, open-label, dose-finding study of GSK2636771, a PI3Kb inhibitor, administered with enzalutamide in patients with metastatic castration-resistant prostate cancer
Sarker, D., Dawson, N. A., Aparicio, A. M., Dorff, T. B., Pantuck, A. J., Vaishampayan, U. N., Henson, L., Vasist, L., Roy-Ghanta, S., Gorczyca, M., York, W., Ganji, G., Tolson, J. & de Bono, J. S., 1 Oct 2021, In: Clinical Cancer Research. 27, 19, p. 5248-5257 10 p.Research output: Contribution to journal › Article › peer-review
Pancreatic cancer exposome profile to aid early detection and inform prevention strategies
Monroy-Iglesias, M. J., Dolly, S., Sarker, D., Thillai, K., Van Hemelrijck, M. & Santaolalla, A., Apr 2021, In: Journal of Clinical Medicine. 10, 8, 1665.Research output: Contribution to journal › Article › peer-review
Apoptosis in the Pancreatic Cancer Tumor Microenvironment-The Double-Edged Sword of Cancer-Associated Fibroblasts
Pfeifer, E., Burchell, J. M., Dazzi, F., Sarker, D. & Beatson, R., 1 Jul 2021, In: Cells. 10, 7, 1653.Research output: Contribution to journal › Review article › peer-review
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Subbiah, V., Hu, M. I., Wirth, L. J., Schuler, M., Mansfield, A. S., Curigliano, G., Brose, M. S., Zhu, V. W., Leboulleux, S., Bowles, D. W., Baik, C. S., Adkins, D., Keam, B., Matos, I., Garralda, E., Gainor, J. F., Lopes, G., Lin, C. C., Godbert, Y. & Sarker, D. & 5 others, Miller, S. G., Clifford, C., Zhang, H., Turner, C. D. & Taylor, M. H., Aug 2021, In: The Lancet Diabetes and Endocrinology. 9, 8, p. 491-501 11 p.Research output: Contribution to journal › Article › peer-review
Apoptosis in the Pancreatic Cancer TumorMicroenvironment— The Double-Edged Sword of Cancer-Associated Fibroblasts
Pfeifer, E., Burchell, J., Dazzi, F., Sarker, D. & Beatson, R., 1 Jul 2021, In: Cells. 10, 1653, 18 p.Research output: Contribution to journal › Review article › peer-review
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison
Trojan, J., Mollon, P., Daniele, B., Marteau, F., Martín, L., Li, Y., Xu, Q., Piscaglia, F., Zaucha, R., Sarker, D., Lim, H. Y. & Venerito, M., May 2021, In: ADVANCES IN THERAPY. 38, 5, p. 2472-2490 19 p.Research output: Contribution to journal › Article › peer-review
Validity of whole genomes sequencing results in neoplasms in precision medicine
Echejoh, G., Liu, Y., Chung-Faye, G., Charlton, J., Moorhead, J., Clark, B., Davidson, P., Sarker, D., Ross, P. & Ooft, M. L., 2020, (Accepted/In press) In: Journal of Clinical Pathology.Research output: Contribution to journal › Article › peer-review
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
Sarker, D., 1 Dec 2020, In: Nature Communications. 11, 1, 4841.Research output: Contribution to journal › Article › peer-review
The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy
Webb, T. E., Davies, M., Maher, J. & Sarker, D., 1 Sept 2020, In: Clinical and Translational Radiation Oncology. 24, p. 123-126 4 p.Research output: Contribution to journal › Article › peer-review
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)
Sarker, D., 5 Feb 2020, In: BMJ Open. 10, 2, e034527.Research output: Contribution to journal › Article › peer-review
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Sarker, D., Plummer, R., Meyer, T., Sodergren, M. H., Basu, B., Chee, C. E., Huang, K.-W., Palmer, D. H., Ma, Y. T., Evans, T. R. J., Spalding, D. R. C., Pai, M., Sharma, R., Pinato, D. J., Spicer, J., Hunter, S., Kwatra, V., Nicholls, J. P., Collin, D. & Nutbrown, R. & 16 others, Glenny, H., Fairbairn, S., Reebye, V., Voutila, J., Dorman, S., Andrikakou, P., Lloyd, P., Felstead, S., Vasara, J., Habib, R., Wood, C., Saetrom, P., Huber, H. E., Blakey, D. C., Rossi, J. J. & Habib, N., 1 Aug 2020, In: Clinical Cancer Research. 26, 15, p. 3936-3946 11 p.Research output: Contribution to journal › Article › peer-review
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor
Plummer, R., Dua, D., Cresti, N., Drew, Y., Stephens, P., Foegh, M., Knudsen, S., Sachdev, P., Mistry, B. M., Dixit, V., McGonigle, S., Hall, N., Matijevic, M., McGrath, S. & Sarker, D., 18 Aug 2020, In: British Journal of Cancer. 123, 4, p. 525-533 9 p.Research output: Contribution to journal › Article › peer-review
Does dose affect tumour response in phase I oncology trials of non-cytotoxic agents?
Ghosh, J., Lazaridis, G., Viney, Z., Verma, H., Sheriff, I., Wang, Y., Moller, H., Spicer, J. F. & Sarker, D., 1 Oct 2016, In: Annals of Oncology. 27, p. vi131Research output: Contribution to journal › Article › peer-review
Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study
Sollie, S., Santaolalla, A., Michaud, D. S., Sarker, D., Karagiannis, S. N., Josephs, D. H., Hammar, N., Walldius, G., Garmo, H., Holmberg, L., Jungner, I. & Van Hemelrijck, M., 28 Feb 2020, In: Frontiers in oncology. 10, p. 263 263.Research output: Contribution to journal › Article › peer-review
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
Kim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J. W., Choo, S. P., Hollebecque, A., Sung, M. W., Lim, H. Y., Mazzaferro, V., Trojan, J., Zhu, A. X., Yoon, J. H., Sharma, S., Lin, Z. Z., Chan, S. L., Faivre, S., Feun, L. G. & Yen, C. J. & 15 others, Dufour, J. F., Palmer, D. H., Llovet, J. M., Manoogian, M., Tugnait, M., Stransky, N., Hagel, M., Kohl, N. E., Lengauer, C., Sherwin, C. A., Schmidt-Kittler, O., Hoeflich, K. P., Shi, H., Wolf, B. B. & Kang, Y. K., 1 Dec 2019, In: Cancer discovery. 9, 12, p. 1696-1707 12 p.Research output: Contribution to journal › Article › peer-review
Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study
Sollie, S., Michaud, D. S., Sarker, D., Karagiannis, S. N., Josephs, D. H., Hammar, N., Santaolalla, A., Walldius, G., Garmo, H., Holmberg, L., Jungner, I. & Van Hemelrijck, M., 29 Aug 2019, (E-pub ahead of print) In: BMC Cancer. 19, 1, 858.Research output: Contribution to journal › Article › peer-review
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
Massard, C., Azaro, A., Soria, J. C., Lassen, U., Le Tourneau, C., Sarker, D., Smith, C., Ohnmacht, U., Oakley, G., Patel, B. K. R., Yuen, E. S. M., Benhadji, K. A. & Rodon, J., 1 Sept 2018, In: Annals of Oncology. 29, 9, p. 1911-1917 7 p.Research output: Contribution to journal › Article › peer-review
Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents
Jordan, E. J., Spicer, J. & Sarker, D., 21 Sept 2018, In: Oncotarget. 9, 74, p. 33961-33971 11 p.Research output: Contribution to journal › Article › peer-review
Hepatocellular Carcinoma as a Complication of Vascular Disease of the Liver After Fontan Procedure
Mazzarelli, C., Cannon, M. D., Hudson, M., Heaton, N., Sarker, D., Kane, P., Quaglia, A. & Suddle, A., 1 Feb 2019, In: Hepatology. 69, 2, p. 911-913 3 p.Research output: Contribution to journal › Article › peer-review
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
O’Brien, M. E. R., Sarker, D., Bhosle, J., Thillai, K., Yap, T. A., Uttenreuther-Fischer, M., Pemberton, K., Jin, X., Wiebe, S., De Bono, J. & Spicer, J., 7 Aug 2018, (E-pub ahead of print) In: Cancer Chemotherapy and Pharmacology.Research output: Contribution to journal › Article › peer-review
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., Sarker, D., Verset, G., Chan, S. L., Knox, J., Daniele, B., Webber, A. L., Ebbinghaus, S. W., Ma, J., Siegel, A. B. & KEYNOTE-224 investigators & 31 others, Cheng, A.-L., Kudo, M., Alistar, A., Asselah, J., Blanc, J.-F., Borbath, I., Cannon, T., Chung, K., Cohn, A., Cosgrove, D. P., Damjanov, N., Gupta, M., Karino, Y., Karwal, M., Kaubisch, A., Kelley, R., Van Laethem, J.-L., Larson, T., Lee, J., Li, D., Manhas, A., Manji, G. A., Numata, K., Parsons, B., Paulson, A. S., Pinto, C., Ramirez, R., Ratnam, S., Rizell, M., Rosmorduc, O. & Sada, Y., 1 Jul 2018, In: The Lancet Oncology. 19, 7, p. 940-952Research output: Contribution to journal › Article › peer-review
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
Abou-Alfa, G. K., Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H. Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W. P., Chen, Z., Hubner, R. A., Meyer, T., Sun, W., Harding, J. J., Hollywood, E. M. & Ma, J. & 7 others, Wan, P. J., Ly, M., Bomalaski, J., Johnston, A., Lin, C.-C., Chao, Y. & Chen, L.-T., 1 Jun 2018, In: Annals of Oncology. 29, 6, p. 1402-1408Research output: Contribution to journal › Article › peer-review
Hepatocellular Carcinoma in Perinatally Acquired HIV and HBV Coinfection: A Case Report
Sarker, D., 2017, In: Pediatric Infectious Disease Journal.Research output: Contribution to journal › Article › peer-review
PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer
Sarker, D., 2018, In: Health Technology Assessment.Research output: Contribution to journal › Article › peer-review
ADI-PEG 20 Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma
Sarker, D., 2018, In: Annals of Oncology.Research output: Contribution to journal › Article › peer-review
PAK4 pathway as a potential therapeutic target in pancreatic cancer
Thillai, K., Sarker, D. & Wells, C., Mar 2018, In: Future Oncology. 14, 7, p. 579-582 4 p.Research output: Contribution to journal › Review article › peer-review
Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream?
Basuroy, R., Sarker, D., Quaglia, A., Srirajaskanthan, R. & Ramage, J., Aug 2015, In: INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY. 2, 3, p. 201-215Research output: Contribution to journal › Article › peer-review
Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series
de Vito, C., Sarker, D., Ross, P., Heaton, N. & Quaglia, A., Nov 2017, In: Virchows Archiv : an international journal of pathology. 471, 5, p. 619-629 11 p.Research output: Contribution to journal › Article › peer-review
Histological Classification of Pancreatic Neuroendocrine Tumours: Optimising the Ki67 System
Mills, L., Ramage, J., Prachalias, A., Srinivasan, P., Menon, K., Heaton, N., Quaglia, A., Vivian, G., Sarker, D., Ross, P., Basuroy, R. & Srirajaskanthan, R., 2015, In: Neuroendocrinology. 102, 1-2, p. 103-103Research output: Contribution to journal › Article › peer-review
Pancreatic Neuroendocrine Incidentalomas: When Is Surgery in the Patient's Best Interests?
Mills, L., Ramage, J., Prachalias, A., Srinivasan, P., Menon, K., Quaglia, A., Vivian, G., Heaton, N., Sarker, D., Ross, P., Basuroy, R. & Srirajaskanthan, R., 2015, In: Neuroendocrinology. 102, 1-2, p. 143-143Research output: Contribution to journal › Meeting abstract › peer-review
THE MANAGEMENT OF INCIDENTALLY DIAGNOSED PANCREATIC NEUROENDOCRINE LESIONS: A NEW TOOL TO EVALUATE RISK OF MALIGNANCY
Mills, L., Ramage, J., Prachalias, A., Srinivasan, P., Menon, K., Quaglia, A., Heaton, N., Sarker, D., Ross, P., Basuroy, R. & Srirajaskanthan, R., Jun 2015, In: Gut. 64, p. A306-A306Research output: Contribution to journal › Meeting abstract › peer-review
Histological Classification of Pancreatic Neuroendocrine Tumors: Optimizing the Ki67 Range for Grade of Tumors
Mills, L., Ramage, J. K., Prachalias, A., Srinivasan, P., Menon, K., Quaglia, A., Vivian, G., Heaton, N., Sarker, D., Ross, P. & Srirajaskanthan, R., Mar 2016, In: Pancreas. 45, 3, p. 479-479Research output: Contribution to journal › Meeting abstract › peer-review
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem
Ziogas, D. C., Papadatos-Pastos, D., Thillai, K., Korantzis, I., Chowdhury, R., Suddle, A., O'Grady, J., Al-Khadimi, G., Allen, N., Heaton, N., Ross, P. J. & Sarker, D., 10 Sept 2016, In: European Journal of Gastroenterology and Hepatology. 29, 1, p. 48-55Research output: Contribution to journal › Article › peer-review
Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?
Thillai, K., Lam, H., Sarker, D. & Wells, C. M., 11 Nov 2016, In: Oncotarget. 8, 8, p. 14173-14191 19 p.Research output: Contribution to journal › Article › peer-review
Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?
Thillai, K., Ross, P. & Sarker, D., 15 Feb 2016, (E-pub ahead of print) In: World journal of gastrointestinal oncology. 8, 2, p. 173-85 13 p.Research output: Contribution to journal › Article › peer-review
Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics
Josephs, D. H. & Sarker, D., 21 Feb 2016, In: Translational Oncogenomics.Research output: Contribution to journal › Article › peer-review
Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells
Alrifai, D., Sarker, D. & Maher, J., Feb 2016, In: Immunopharmacology and Immunotoxicology. 38, 1, p. 50-60Research output: Contribution to journal › Article › peer-review
Research
Programme in Gastrointestinal Cancer
The Programme in GI Cancer focuses on GI tract diseases, mostly cancer and oesophago-gastric cancer. This group spans a broad field of interests, promoting collaborative working within KCL, nationally and internationally.
Cancer Early Phase Trials Unit
Led by Professor James Spicer, Dr Debashis Sarker and Dr Rebecca Kristeleit, the Cancer Early Phase Trials Unit focuses on the discovery and development of novel molecular and cellular cancer immunotherapies.
Experimental Oncology
The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.
Project status: Ongoing
Hepatobiliary neoplasms
King’s College Hospital hosts one of Europe’s largest hepato-pancreato-biliary cancer clinical services.
King’s Health Partners ECMC
King’s Health Partners ECMC focuses particularly on new Molecular and Cellular cancer immunotherapies, building on recent translation of agents discovered in King’s laboratories.
News
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.
COVID reforms in cancer care and research could have long-term benefits
A new review led by Professor James Spicer considers the reforms in cancer care and research made due to the pandemic, arguing that some have left a positive...
Experimental cancer treatments receive funding boost
King's Health Partners (KHP) Experimental Cancer Medicine Centre (ECMC) has had its funding renewed for the next five years.
A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases
Plummer, R., Greystoke, A., Naylor, G., Sarker, D., Anam, A. K., Prenen, H., Teuwen, L. A., Van Cutsem, E., Dekervel, J., Haugk, B., Ness, T., Bhoi, S., Jensen, M., Morris, T., Baumann, P., Sjögren, N., Tunblad, K., Wallberg, H., Öberg, F. & Evans, T. R. J., 2024, In: Journal of Hepatocellular Carcinoma. 11, p. 2033-2047 15 p.Research output: Contribution to journal › Article › peer-review
Next-generation sequencing and molecular therapy
Morton, C., Sarker, D. & Ross, P., Jan 2023, In: Clinical Medicine, Journal of the Royal College of Physicians of London. 23, 1, p. 65-69 5 p.Research output: Contribution to journal › Article › peer-review
Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma
Ryoo, B.-Y., Palmer, D. H., Park, S. R., Rimassa, L., Sarker, D., Daniele, B., Steinberg, J., López, B. & Lim, H. Y., Mar 2022, In: CLINICAL DRUG INVESTIGATION. 42, 3, p. 283Research output: Contribution to journal › Article › peer-review
Next-generation sequencing and molecular therapy
Morton, C., Sarker, D. & Ross, P., Jan 2023, In: Clinical medicine (London, England). 23, 1, p. 65-69 5 p.Research output: Contribution to journal › Article › peer-review
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer
Jones, R., Plummer, R., Moreno, V., Carter, L., Roda, D., Garralda, E., Kristeleit, R., Sarker, D., Arkenau, T., Roxburgh, P., Walter, H. S., Blagden, S., Anthoney, A., Klencke, B. J., Kowalski, M. M. & Banerji, U., 15 Jan 2023, In: Clinical Cancer Research. 29, 2, p. 331-340 10 p.Research output: Contribution to journal › Article › peer-review
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer
Kristeleit, R., Plummer, R., Jones, R., Carter, L., Blagden, S., Sarker, D., Arkenau, T., Evans, T. R. J., Danson, S., Symeonides, S. N., Veal, G. J., Klencke, B. J., Kowalski, M. M. & Banerji, U., 27 Jul 2023, In: British journal of cancer. 129, 1, p. 38-45 8 p.Research output: Contribution to journal › Article › peer-review
CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells
Samain, R., Maiques, O., Monger, J., Lam, H., Candido, J., George, S., Ferrari, N., Kohihammer, L., Lunetto, S., Varela, A., Orgaz, J. L., Vilardell, F., Olsina, J. J., Matias-Guiu, X., Sarker, D., Biddle, A., Balkwill, F. R., Eyles, J., Wilkinson, R. W. & Kocher, H. M. & 3 others, Calvo, F., Wells, C. M. & Sanz-Moreno, V., 2023, In: Science Advances. 9, 42, adi0244.Research output: Contribution to journal › Article › peer-review
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer
Propper, D. J., Gao, F., Saunders, M. P., Sarker, D., Hartley, J. A., Spanswick, V. J., Lowe, H. L., Hackett, L. D., Ng, T. T., Barber, P. R., Weitsman, G. E., Pearce, S., White, L., Lopes, A., Forsyth, S. & Hochhauser, D., 19 Jan 2023, In: British journal of cancer. 128, 2, p. 245-254 10 p.Research output: Contribution to journal › Article › peer-review
Revitalising cancer trials post-pandemic: time for reform
Morton, C., Sullivan, R., Sarker, D., Posner, J. & Spicer, J., 12 Apr 2023, In: British journal of cancer. 128, 8, p. 1409-1414 6 p.Research output: Contribution to journal › Article › peer-review
Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Verset, G., Borbath, I., Karwal, M., Verslype, C., Van Vlierberghe, H., Kardosh, A., Zagonel, V., Stal, P., Sarker, D., Palmer, D. H., Vogel, A., Edeline, J., Cattan, S., Kudo, M., Cheng, A. L., Ogasawara, S., Daniele, B., Chan, S. L., Knox, J. J. & Qin, S. & 6 others, Siegel, A. B., Chisamore, M., Hatogai, K., Wang, A., Finn, R. S. & Zhu, A. X., 15 Jun 2022, In: Clinical Cancer Research. 28, 12, p. 2547-2554 8 p.Research output: Contribution to journal › Review article › peer-review
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
KEYNOTE-224 investigators, May 2022, In: European Journal of Cancer. 167, p. 1-12 12 p.Research output: Contribution to journal › Article › peer-review
Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation-Results from the MACPIE-I study
Kundalia, K., Hakeem, A., Papoulas, M., Mcphail, M., Reddy, S., Peddu, P., Kibriya, N., Atkinson, S., Prachalias, A., Srinivasan, P., Heaton, N., Sarker, D., Ross, P., Zen, Y. & Menon, K., Oct 2021, In: European Journal of Surgical Oncology. 47, 10, p. 2571-2578 8 p.Research output: Contribution to journal › Article › peer-review
Upregulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer
Hashimoto, A., Sarker, D., Reebye, V., Jarvis, S., Sodergren, M. H., Kossenkov, A., Sanseviero, E., Raulf, N., Vasara, J., Andrikakou, P., Meyer, T., Huang, K. W., Plummer, R., Chee, C. E., Spalding, D., Pai, M., Khan, S., Pinato, D. J., Sharma, R. & Basu, B. & 11 others, Palmer, D., Ma, Y. T., Evans, J., Habib, R., Martirosyan, A., Elasri, N., Reynaud, A., Rossi, J. J., Cobbold, M., Habib, N. A. & Gabrilovich, D. I., 15 Nov 2021, In: Clinical Cancer Research. 27, 21, p. 5961-5978 18 p.Research output: Contribution to journal › Article › peer-review
A phase I, open-label, dose-finding study of GSK2636771, a PI3Kb inhibitor, administered with enzalutamide in patients with metastatic castration-resistant prostate cancer
Sarker, D., Dawson, N. A., Aparicio, A. M., Dorff, T. B., Pantuck, A. J., Vaishampayan, U. N., Henson, L., Vasist, L., Roy-Ghanta, S., Gorczyca, M., York, W., Ganji, G., Tolson, J. & de Bono, J. S., 1 Oct 2021, In: Clinical Cancer Research. 27, 19, p. 5248-5257 10 p.Research output: Contribution to journal › Article › peer-review
Pancreatic cancer exposome profile to aid early detection and inform prevention strategies
Monroy-Iglesias, M. J., Dolly, S., Sarker, D., Thillai, K., Van Hemelrijck, M. & Santaolalla, A., Apr 2021, In: Journal of Clinical Medicine. 10, 8, 1665.Research output: Contribution to journal › Article › peer-review
Apoptosis in the Pancreatic Cancer Tumor Microenvironment-The Double-Edged Sword of Cancer-Associated Fibroblasts
Pfeifer, E., Burchell, J. M., Dazzi, F., Sarker, D. & Beatson, R., 1 Jul 2021, In: Cells. 10, 7, 1653.Research output: Contribution to journal › Review article › peer-review
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
Subbiah, V., Hu, M. I., Wirth, L. J., Schuler, M., Mansfield, A. S., Curigliano, G., Brose, M. S., Zhu, V. W., Leboulleux, S., Bowles, D. W., Baik, C. S., Adkins, D., Keam, B., Matos, I., Garralda, E., Gainor, J. F., Lopes, G., Lin, C. C., Godbert, Y. & Sarker, D. & 5 others, Miller, S. G., Clifford, C., Zhang, H., Turner, C. D. & Taylor, M. H., Aug 2021, In: The Lancet Diabetes and Endocrinology. 9, 8, p. 491-501 11 p.Research output: Contribution to journal › Article › peer-review
Apoptosis in the Pancreatic Cancer TumorMicroenvironment— The Double-Edged Sword of Cancer-Associated Fibroblasts
Pfeifer, E., Burchell, J., Dazzi, F., Sarker, D. & Beatson, R., 1 Jul 2021, In: Cells. 10, 1653, 18 p.Research output: Contribution to journal › Review article › peer-review
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison
Trojan, J., Mollon, P., Daniele, B., Marteau, F., Martín, L., Li, Y., Xu, Q., Piscaglia, F., Zaucha, R., Sarker, D., Lim, H. Y. & Venerito, M., May 2021, In: ADVANCES IN THERAPY. 38, 5, p. 2472-2490 19 p.Research output: Contribution to journal › Article › peer-review
Validity of whole genomes sequencing results in neoplasms in precision medicine
Echejoh, G., Liu, Y., Chung-Faye, G., Charlton, J., Moorhead, J., Clark, B., Davidson, P., Sarker, D., Ross, P. & Ooft, M. L., 2020, (Accepted/In press) In: Journal of Clinical Pathology.Research output: Contribution to journal › Article › peer-review
Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
Sarker, D., 1 Dec 2020, In: Nature Communications. 11, 1, 4841.Research output: Contribution to journal › Article › peer-review
The eIF4A inhibitor silvestrol sensitizes T-47D ductal breast carcinoma cells to external-beam radiotherapy
Webb, T. E., Davies, M., Maher, J. & Sarker, D., 1 Sept 2020, In: Clinical and Translational Radiation Oncology. 24, p. 123-126 4 p.Research output: Contribution to journal › Article › peer-review
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)
Sarker, D., 5 Feb 2020, In: BMJ Open. 10, 2, e034527.Research output: Contribution to journal › Article › peer-review
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial
Sarker, D., Plummer, R., Meyer, T., Sodergren, M. H., Basu, B., Chee, C. E., Huang, K.-W., Palmer, D. H., Ma, Y. T., Evans, T. R. J., Spalding, D. R. C., Pai, M., Sharma, R., Pinato, D. J., Spicer, J., Hunter, S., Kwatra, V., Nicholls, J. P., Collin, D. & Nutbrown, R. & 16 others, Glenny, H., Fairbairn, S., Reebye, V., Voutila, J., Dorman, S., Andrikakou, P., Lloyd, P., Felstead, S., Vasara, J., Habib, R., Wood, C., Saetrom, P., Huber, H. E., Blakey, D. C., Rossi, J. J. & Habib, N., 1 Aug 2020, In: Clinical Cancer Research. 26, 15, p. 3936-3946 11 p.Research output: Contribution to journal › Article › peer-review
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor
Plummer, R., Dua, D., Cresti, N., Drew, Y., Stephens, P., Foegh, M., Knudsen, S., Sachdev, P., Mistry, B. M., Dixit, V., McGonigle, S., Hall, N., Matijevic, M., McGrath, S. & Sarker, D., 18 Aug 2020, In: British Journal of Cancer. 123, 4, p. 525-533 9 p.Research output: Contribution to journal › Article › peer-review
Does dose affect tumour response in phase I oncology trials of non-cytotoxic agents?
Ghosh, J., Lazaridis, G., Viney, Z., Verma, H., Sheriff, I., Wang, Y., Moller, H., Spicer, J. F. & Sarker, D., 1 Oct 2016, In: Annals of Oncology. 27, p. vi131Research output: Contribution to journal › Article › peer-review
Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study
Sollie, S., Santaolalla, A., Michaud, D. S., Sarker, D., Karagiannis, S. N., Josephs, D. H., Hammar, N., Walldius, G., Garmo, H., Holmberg, L., Jungner, I. & Van Hemelrijck, M., 28 Feb 2020, In: Frontiers in oncology. 10, p. 263 263.Research output: Contribution to journal › Article › peer-review
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
Kim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J. W., Choo, S. P., Hollebecque, A., Sung, M. W., Lim, H. Y., Mazzaferro, V., Trojan, J., Zhu, A. X., Yoon, J. H., Sharma, S., Lin, Z. Z., Chan, S. L., Faivre, S., Feun, L. G. & Yen, C. J. & 15 others, Dufour, J. F., Palmer, D. H., Llovet, J. M., Manoogian, M., Tugnait, M., Stransky, N., Hagel, M., Kohl, N. E., Lengauer, C., Sherwin, C. A., Schmidt-Kittler, O., Hoeflich, K. P., Shi, H., Wolf, B. B. & Kang, Y. K., 1 Dec 2019, In: Cancer discovery. 9, 12, p. 1696-1707 12 p.Research output: Contribution to journal › Article › peer-review
Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study
Sollie, S., Michaud, D. S., Sarker, D., Karagiannis, S. N., Josephs, D. H., Hammar, N., Santaolalla, A., Walldius, G., Garmo, H., Holmberg, L., Jungner, I. & Van Hemelrijck, M., 29 Aug 2019, (E-pub ahead of print) In: BMC Cancer. 19, 1, 858.Research output: Contribution to journal › Article › peer-review
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer
Massard, C., Azaro, A., Soria, J. C., Lassen, U., Le Tourneau, C., Sarker, D., Smith, C., Ohnmacht, U., Oakley, G., Patel, B. K. R., Yuen, E. S. M., Benhadji, K. A. & Rodon, J., 1 Sept 2018, In: Annals of Oncology. 29, 9, p. 1911-1917 7 p.Research output: Contribution to journal › Article › peer-review
Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents
Jordan, E. J., Spicer, J. & Sarker, D., 21 Sept 2018, In: Oncotarget. 9, 74, p. 33961-33971 11 p.Research output: Contribution to journal › Article › peer-review
Hepatocellular Carcinoma as a Complication of Vascular Disease of the Liver After Fontan Procedure
Mazzarelli, C., Cannon, M. D., Hudson, M., Heaton, N., Sarker, D., Kane, P., Quaglia, A. & Suddle, A., 1 Feb 2019, In: Hepatology. 69, 2, p. 911-913 3 p.Research output: Contribution to journal › Article › peer-review
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
O’Brien, M. E. R., Sarker, D., Bhosle, J., Thillai, K., Yap, T. A., Uttenreuther-Fischer, M., Pemberton, K., Jin, X., Wiebe, S., De Bono, J. & Spicer, J., 7 Aug 2018, (E-pub ahead of print) In: Cancer Chemotherapy and Pharmacology.Research output: Contribution to journal › Article › peer-review
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., Sarker, D., Verset, G., Chan, S. L., Knox, J., Daniele, B., Webber, A. L., Ebbinghaus, S. W., Ma, J., Siegel, A. B. & KEYNOTE-224 investigators & 31 others, Cheng, A.-L., Kudo, M., Alistar, A., Asselah, J., Blanc, J.-F., Borbath, I., Cannon, T., Chung, K., Cohn, A., Cosgrove, D. P., Damjanov, N., Gupta, M., Karino, Y., Karwal, M., Kaubisch, A., Kelley, R., Van Laethem, J.-L., Larson, T., Lee, J., Li, D., Manhas, A., Manji, G. A., Numata, K., Parsons, B., Paulson, A. S., Pinto, C., Ramirez, R., Ratnam, S., Rizell, M., Rosmorduc, O. & Sada, Y., 1 Jul 2018, In: The Lancet Oncology. 19, 7, p. 940-952Research output: Contribution to journal › Article › peer-review
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
Abou-Alfa, G. K., Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H. Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W. P., Chen, Z., Hubner, R. A., Meyer, T., Sun, W., Harding, J. J., Hollywood, E. M. & Ma, J. & 7 others, Wan, P. J., Ly, M., Bomalaski, J., Johnston, A., Lin, C.-C., Chao, Y. & Chen, L.-T., 1 Jun 2018, In: Annals of Oncology. 29, 6, p. 1402-1408Research output: Contribution to journal › Article › peer-review
Hepatocellular Carcinoma in Perinatally Acquired HIV and HBV Coinfection: A Case Report
Sarker, D., 2017, In: Pediatric Infectious Disease Journal.Research output: Contribution to journal › Article › peer-review
PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer
Sarker, D., 2018, In: Health Technology Assessment.Research output: Contribution to journal › Article › peer-review
ADI-PEG 20 Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma
Sarker, D., 2018, In: Annals of Oncology.Research output: Contribution to journal › Article › peer-review
PAK4 pathway as a potential therapeutic target in pancreatic cancer
Thillai, K., Sarker, D. & Wells, C., Mar 2018, In: Future Oncology. 14, 7, p. 579-582 4 p.Research output: Contribution to journal › Review article › peer-review
Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream?
Basuroy, R., Sarker, D., Quaglia, A., Srirajaskanthan, R. & Ramage, J., Aug 2015, In: INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY. 2, 3, p. 201-215Research output: Contribution to journal › Article › peer-review
Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series
de Vito, C., Sarker, D., Ross, P., Heaton, N. & Quaglia, A., Nov 2017, In: Virchows Archiv : an international journal of pathology. 471, 5, p. 619-629 11 p.Research output: Contribution to journal › Article › peer-review
Histological Classification of Pancreatic Neuroendocrine Tumours: Optimising the Ki67 System
Mills, L., Ramage, J., Prachalias, A., Srinivasan, P., Menon, K., Heaton, N., Quaglia, A., Vivian, G., Sarker, D., Ross, P., Basuroy, R. & Srirajaskanthan, R., 2015, In: Neuroendocrinology. 102, 1-2, p. 103-103Research output: Contribution to journal › Article › peer-review
Pancreatic Neuroendocrine Incidentalomas: When Is Surgery in the Patient's Best Interests?
Mills, L., Ramage, J., Prachalias, A., Srinivasan, P., Menon, K., Quaglia, A., Vivian, G., Heaton, N., Sarker, D., Ross, P., Basuroy, R. & Srirajaskanthan, R., 2015, In: Neuroendocrinology. 102, 1-2, p. 143-143Research output: Contribution to journal › Meeting abstract › peer-review
THE MANAGEMENT OF INCIDENTALLY DIAGNOSED PANCREATIC NEUROENDOCRINE LESIONS: A NEW TOOL TO EVALUATE RISK OF MALIGNANCY
Mills, L., Ramage, J., Prachalias, A., Srinivasan, P., Menon, K., Quaglia, A., Heaton, N., Sarker, D., Ross, P., Basuroy, R. & Srirajaskanthan, R., Jun 2015, In: Gut. 64, p. A306-A306Research output: Contribution to journal › Meeting abstract › peer-review
Histological Classification of Pancreatic Neuroendocrine Tumors: Optimizing the Ki67 Range for Grade of Tumors
Mills, L., Ramage, J. K., Prachalias, A., Srinivasan, P., Menon, K., Quaglia, A., Vivian, G., Heaton, N., Sarker, D., Ross, P. & Srirajaskanthan, R., Mar 2016, In: Pancreas. 45, 3, p. 479-479Research output: Contribution to journal › Meeting abstract › peer-review
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem
Ziogas, D. C., Papadatos-Pastos, D., Thillai, K., Korantzis, I., Chowdhury, R., Suddle, A., O'Grady, J., Al-Khadimi, G., Allen, N., Heaton, N., Ross, P. J. & Sarker, D., 10 Sept 2016, In: European Journal of Gastroenterology and Hepatology. 29, 1, p. 48-55Research output: Contribution to journal › Article › peer-review
Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?
Thillai, K., Lam, H., Sarker, D. & Wells, C. M., 11 Nov 2016, In: Oncotarget. 8, 8, p. 14173-14191 19 p.Research output: Contribution to journal › Article › peer-review
Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?
Thillai, K., Ross, P. & Sarker, D., 15 Feb 2016, (E-pub ahead of print) In: World journal of gastrointestinal oncology. 8, 2, p. 173-85 13 p.Research output: Contribution to journal › Article › peer-review
Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics
Josephs, D. H. & Sarker, D., 21 Feb 2016, In: Translational Oncogenomics.Research output: Contribution to journal › Article › peer-review
Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells
Alrifai, D., Sarker, D. & Maher, J., Feb 2016, In: Immunopharmacology and Immunotoxicology. 38, 1, p. 50-60Research output: Contribution to journal › Article › peer-review
Research
Programme in Gastrointestinal Cancer
The Programme in GI Cancer focuses on GI tract diseases, mostly cancer and oesophago-gastric cancer. This group spans a broad field of interests, promoting collaborative working within KCL, nationally and internationally.
Cancer Early Phase Trials Unit
Led by Professor James Spicer, Dr Debashis Sarker and Dr Rebecca Kristeleit, the Cancer Early Phase Trials Unit focuses on the discovery and development of novel molecular and cellular cancer immunotherapies.
Experimental Oncology
The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.
Project status: Ongoing
Hepatobiliary neoplasms
King’s College Hospital hosts one of Europe’s largest hepato-pancreato-biliary cancer clinical services.
King’s Health Partners ECMC
King’s Health Partners ECMC focuses particularly on new Molecular and Cellular cancer immunotherapies, building on recent translation of agents discovered in King’s laboratories.
News
Experimental mRNA cancer vaccine shows potential for advanced stage cancer patients
Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.
COVID reforms in cancer care and research could have long-term benefits
A new review led by Professor James Spicer considers the reforms in cancer care and research made due to the pandemic, arguing that some have left a positive...
Experimental cancer treatments receive funding boost
King's Health Partners (KHP) Experimental Cancer Medicine Centre (ECMC) has had its funding renewed for the next five years.